Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: locally advanced unresectable or metastatic HER2-negative, CLDN18
I · Intervention 중재 / 시술
zolbetuximab with modified folinic acid, 5-FU, and oxaliplatin
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This study utilized population pharmacokinetic (PopPK) analysis to address these limitations.
[PURPOSE] Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), is approved in combination with chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-pos
APA
Yamada A, Yang J, et al. (2025). Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.. Cancer chemotherapy and pharmacology, 95(1), 89. https://doi.org/10.1007/s00280-025-04808-2
MLA
Yamada A, et al.. "Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.." Cancer chemotherapy and pharmacology, vol. 95, no. 1, 2025, pp. 89.
PMID
40970968
Abstract
[PURPOSE] Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), is approved in combination with chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer (in Japan) and in combination with fluoropyrimidine- and platinum-containing chemotherapy for first-line locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (in geographies including but not limited to the US, Europe, and China). Noncompartmental analysis (NCA) was previously used to evaluate the effect of zolbetuximab on pharmacokinetics (PK) of 5-fluorouracil (5-FU) and oxaliplatin; however, limitations of NCA confounded the results. This study utilized population pharmacokinetic (PopPK) analysis to address these limitations.
[METHODS] In Cohort 2 of the phase 2 ILUSTRO study (NCT03505320), patients with locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive G/GEJ adenocarcinoma received zolbetuximab with modified folinic acid, 5-FU, and oxaliplatin. PopPK models were developed to evaluate the impact of zolbetuximab on PK of 5-FU and oxaliplatin (including simultaneous analysis of free and total platinum).
[RESULTS] PK of 5-FU was adequately described by a 1-compartment model with zero-order input and first-order elimination. PK of free and total platinum was simultaneously described by a 3-compartment model with zero-order input, first-order elimination, and time-dependent free fraction. No impact of zolbetuximab on 5-FU PK or on systemic clearance or free fraction of oxaliplatin in plasma was observed. The effect of zolbetuximab on oxaliplatin distribution volume (12.3% decrease) was statistically significant but not considered clinically relevant.
[CONCLUSION] PopPK analysis suggests no effect of zolbetuximab on 5-FU or oxaliplatin PK.
[METHODS] In Cohort 2 of the phase 2 ILUSTRO study (NCT03505320), patients with locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive G/GEJ adenocarcinoma received zolbetuximab with modified folinic acid, 5-FU, and oxaliplatin. PopPK models were developed to evaluate the impact of zolbetuximab on PK of 5-FU and oxaliplatin (including simultaneous analysis of free and total platinum).
[RESULTS] PK of 5-FU was adequately described by a 1-compartment model with zero-order input and first-order elimination. PK of free and total platinum was simultaneously described by a 3-compartment model with zero-order input, first-order elimination, and time-dependent free fraction. No impact of zolbetuximab on 5-FU PK or on systemic clearance or free fraction of oxaliplatin in plasma was observed. The effect of zolbetuximab on oxaliplatin distribution volume (12.3% decrease) was statistically significant but not considered clinically relevant.
[CONCLUSION] PopPK analysis suggests no effect of zolbetuximab on 5-FU or oxaliplatin PK.
MeSH Terms
Humans; Oxaliplatin; Stomach Neoplasms; Fluorouracil; Adenocarcinoma; Esophagogastric Junction; Antineoplastic Combined Chemotherapy Protocols; Male; Female; Middle Aged; Aged; Esophageal Neoplasms; Adult; Models, Biological
같은 제1저자의 인용 많은 논문 (5)
- Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insurance.
- Individualized risk stratification for postmastectomy radiation therapy in node-positive breast cancer: moving beyond universal guidelines.
- Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.
- Use of Handheld Ultrasound for Flap Monitoring after Free Jejunal Transfer.
- Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers.